Study Validates Ambry Genetics' Digital Tool for Accurate Hereditary Cancer Risk Assessment

Ambry Genetics, a leading provider of clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), has announced that a peer-reviewed study validating the accuracy of its Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. The study, titled "Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer," demonstrates the effectiveness and reliability of the Ambry CARE Program in accurately identifying patients who may benefit from genetic testing for hereditary cancers. This digital tool leverages national testing guidelines to ensure that those at high risk are appropriately referred for further evaluation and testing. Hereditary cancer risk assessment is crucial for early detection and prevention. By accurately identifying high-risk individuals, healthcare providers can offer targeted interventions, such as increased surveillance and preventive measures, significantly improving patient outcomes. The Ambry CARE Program streamlines this process, making it more accessible and efficient for both clinicians and patients. The publication of this validation study in a respected journal underscores the scientific rigor behind Ambry Genetics’ innovative approach to genetic testing. Jason Beyer, CEO of Tempus AI, commented on the significance of the findings: “This study provides robust evidence that the Ambry CARE Program is a reliable and effective tool in hereditary cancer risk assessment. It is a testament to our commitment to advancing precision medicine and ensuring that patients receive the most accurate and pertinent genetic information.” As hereditary cancer continues to be a significant public health concern, the Ambry CARE Program offers a promising solution for identifying at-risk individuals more effectively. This digital tool not only enhances the accuracy of risk assessments but also supports the broader goal of personalized healthcare, which is increasingly recognized as essential for improving patient care and outcomes.